Yen Chih-Chieh, Yen Chia-Jui, Shan Yan-Shen, Lin Yih-Jyh, Liu I-Ting, Huang Hsuan-Yi, Yeh Matthew M, Chan Shih-Huang, Tsai Hung-Wen
Division of Haematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital DouLiuo Branch, Yunlin, Taiwan.
Institute of Clinical Medicine, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan.
Histopathology. 2021 Oct;79(4):556-572. doi: 10.1111/his.14384. Epub 2021 Jun 23.
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is an uncommon hepatic malignancy with a poor outcome. The 2019 World Health Organization (WHO) classification modified the definition and discarded the subtypes with stem cell features. However, the differences among cHCC-CCA, hepatocellular carcinoma (HCC), HCC with stem cell/progenitor features (HCCscf) and intrahepatic cholangiocarcinoma (iCCA) remain undetermined. The aim of this study was to investigate the characteristics of cHCC-CCA in comparison with those of other primary liver cancers by utilising the updated WHO classification.
We retrospectively analysed 64 cHCC-CCA patients and 55 HCCscf patients from December 2007 to May 2018. Propensity score matching was conducted to compare these with HCC and iCCA patients. Clinicopathological characteristics, event-free survival and overall survival were evaluated with multivariate Cox proportional hazard regression. During a median follow-up of 55.9 months, cHCC-CCA patients had significantly poorer survival than HCCscf patients, and survival intermediate between that of HCC patients and that of iCCA patients. Hepatitis B virus (HBV) infection and high levels of tumour-infiltrating lymphocytes (TILs) were associated with favourable survival in cHCC-CCA patients. In the multivariate analysis, poor hepatic reserve, absence of HBV infection, stage IV disease and low levels of TILs were significant negative prognostic factors in cHCC-CCA patients. After being pooled with other primary liver cancers, cHCC-CCA and iCCA resulted in the worse survival.
cHCC-CCA patients have survival intermediate between that of HCC patients and iCCA patients, and HBV infection and high levels of TILs predict favourable survival. Our study provides clinical correlations for the new 2019 WHO classification.
肝内胆管癌合并肝细胞癌(cHCC-CCA)是一种罕见的肝脏恶性肿瘤,预后较差。2019年世界卫生组织(WHO)分类修改了定义并摒弃了具有干细胞特征的亚型。然而,cHCC-CCA、肝细胞癌(HCC)、具有干细胞/祖细胞特征的HCC(HCCscf)和肝内胆管癌(iCCA)之间的差异仍未明确。本研究的目的是利用更新后的WHO分类,调查cHCC-CCA与其他原发性肝癌相比的特征。
我们回顾性分析了2007年12月至2018年5月期间的64例cHCC-CCA患者和55例HCCscf患者。进行倾向评分匹配以将这些患者与HCC和iCCA患者进行比较。采用多变量Cox比例风险回归评估临床病理特征、无事件生存期和总生存期。在中位随访55.9个月期间,cHCC-CCA患者的生存期明显比HCCscf患者差,生存期介于HCC患者和iCCA患者之间。乙型肝炎病毒(HBV)感染和高水平的肿瘤浸润淋巴细胞(TILs)与cHCC-CCA患者的良好生存期相关。在多变量分析中,肝储备功能差、无HBV感染、IV期疾病和低水平的TILs是cHCC-CCA患者显著的不良预后因素。与其他原发性肝癌合并后,cHCC-CCA和iCCA导致更差的生存期。
cHCC-CCA患者的生存期介于HCC患者和iCCA患者之间,HBV感染和高水平的TILs预示良好的生存期。我们的研究为2019年WHO新分类提供了临床相关性。